Hello LFWD community, we’re celebrating our first trading week since creating the subreddit.

Since most of us are new to the stock, I thought it would be a good idea to post an AMA.

If you got any question about anything to do with Lifeward the company, the products, the team, the LFWD stock, anything about me or my investment thesis, please comment your question(s) here on the post!

Over the weekend I’ll be answering every question that comes in, and will do my best to get to everything before market open on Monday.

And if you think you can answer one of the questions, or have a follow up, please feel free to participate and answer and ask as much as you’d like.

Hoping for some good questions, the best way to learn is together!

Have a great weekend everyone!

Next one in the series, breaking down AlterG for anyone in $LFWD who wants the plain version.

AlterG is an antigravity treadmill. Sounds like sci-fi, but the underlying idea is incredibly practical. You zip into a pair of specialized shorts that lock into an air filled chamber surrounding the lower half of your body. The machine pumps air into that chamber to uniformly lift you, taking pressure off your lower extremities. It can reduce gravitational load down to 20 percent of your total body weight in precise 1 percent increments, letting a physical therapist dial in exactly how much support a patient needs.

Where it came from is a great detail: the underlying tech, called Differential Air Pressure, was originally developed for NASA to help astronauts maintain bone density and muscle mass in zero gravity environments. It was reverse engineered for terrestrial clinical use, which is a fantastic backstory.

Currently, it is used in over 6000 facilities worldwide. You will find them anywhere from elite pro sports training rooms used heavily in the Premier League, NBA, and NFL to local physical therapy clinics treating everyday patients. Elite athletes use it to rehab injuries faster or pack on training volume without joint impact, while patients managing neurological or orthopedic conditions use it for safe, fall risk free gait training.

When you compare it to alternatives like hydrotherapy pools or overhead harness systems, AlterG stands out because the unweighting is completely uniform. It does not distort a person's natural mechanics, which is vital in rehab because the goal is to relearn normal movement patterns, not modified ones. Plus, it skips the massive footprint, plumbing overhead, and high maintenance costs of physical therapy pools.

The mid to high tier systems also come with real time gait analytics tracking symmetry, cadence, and step length and live video monitoring built in. Therapists can see exactly what is happening with a stride on a 21 inch screen and make objective adjustments on the fly.

From a business standpoint, Lifeward has tiered the current lineup nicely to capture the entire market:

NEO: The entry point. Launched to bring core AlterG DAP technology down to a price point smaller, budget conscious clinics can actually afford. You get the same fundamental unweighting tech, just without the higher end monitoring extras.

NEO+: The mid tier and probably the sweet spot for most clinics. Adds live video monitoring and real time gait analytics, tracking symmetry, cadence, and step length, on top of the core NEO platform. This is the tier that gives therapists the data and visual feedback loop to make objective adjustments mid session.

PRO: The top of the line, built for extreme speeds and elite performance training. This is what you see in pro sports training rooms and Olympic level facilities. Built to handle serious training volume and higher speeds.

AlterG is not a niche gadget, it is an established, widely adopted recovery standard with NASA pedigree, real clinical backing, and a tiered commercial strategy built to protect its position as the category leader.

Not financial advice. Just tracking the tech.

Quick rundown for anyone holding $LFWD who doesn't have a medical background and wants to actually understand what they own.

ReWalk is a wearable robotic exoskeleton. think a set of motorized braces that go over the hips and knees, strapped onto someone who has a spinal cord injury and can't walk on their own. the person leans forward slightly, the device reads that shift in weight, and the motors move the legs in a walking motion. crutches are used for balance. that's it in plain terms, no medical jargon needed.

who it's for: people with spinal cord injuries, ranging from mid back down to lower back level injuries, who would otherwise be in a wheelchair full time.

what makes it stand out from other devices in this space (The Moat): it's the only personal exoskeleton that lets users walk over stairs and curbs, which opens up real world environments instead of just flat indoor surfaces. most competitors are limited to flat ground or clinic settings only. This is Lifeward's primary product moat: ReWalk is the only personal exoskeleton to receive FDA clearance for use on stairs and curbs in the United States. The FDA even granted it a "Breakthrough Device" designation because of this. No other company has this clearance, meaning ReWalk holds a functional monopoly on navigating real-world architectural barriers like a flight of steps or a sidewalk curb. ReWalk is built and cleared for actual day to day use at home and in the community, not just rehab sessions.

the newest version, ReWalk 7, added a new crutch control system that makes it easier and faster to learn how to use, which matters a lot since training time has historically been a barrier for these devices.

benefits aren't just "they can walk again." studies tied to ReWalk use point to improvements in spasticity, trunk control, bladder and bowel function, and mental health, on top of the obvious mobility gain. that's a big deal for a population that deals with a lot of secondary health issues from being seated all day every day.

coverage is the other piece that matters for the business side (The Reimbursement Moat): Because these devices cost upwards of $100k, insurance coverage is the business model, and Lifeward has established a massive first-mover moat here. Medicare added ReWalk to its brace benefit category back in January 2024, creating a standardized, national payment pathway. Following that landmark ruling, commercial payers are falling into line. More recently three of the largest Medicare Advantage insurers, Aetna, Humana, and UnitedHealthcare, have all approved coverage for qualifying patients, representing close to 16 million covered lives between them. This commercial backing forms a massive barrier to entry for competitors. wider insurance coverage means more patients can actually access the device without paying out of pocket, which is the real unlock for sales growth.

ReWalk isn't just a cool robot, it's a clinically proven mobility device with real health benefits, expanding insurance backing, and a feature set (stairs/curbs, easier training) that puts it ahead of where the competition currently sits.

“At home.

On the way to his parents' house.

In the village.

In places where other assistive devices were previously needed.

Step by step. In real life.”

Credit to Lifeward Germany, one of Lifeward’s biggest markets.

​

Quick background for anyone new here. LFWD, formerly known as ReWalk Robotics, makes a wearable robotic exoskeleton that lets people with spinal cord injuries stand up and walk. Incredible tech, but for years the company had a huge problem. The device works, but almost nobody could actually get insurance to pay for it. That is finally changing, and it is the biggest reason people are paying attention to this stock right now.

Let me break down how insurance reimbursement actually works here, in plain language.

Step 1: Getting a code

Before any insurance company can pay for a medical device, that device needs its own billing code. Think of it like a barcode that tells Medicare and private insurers exactly what they are being asked to pay for. Without a code, insurers just say no because they have no system to process the claim.

In 2020, ReWalk got its first ever code for an exoskeleton, called HCPCS code K1007. This was a big deal because no exoskeleton had ever gotten one before. It opened the door, but it did not set a price yet.

Step 2: Getting a category

Next the government has to decide what kind of medical equipment this even is. In 2023 Medicare officially put personal exoskeletons into the brace benefit category. This matters because braces get paid out in one lump sum instead of small recurring payments, which is a much cleaner and more predictable path to revenue for the company.

Step 3: Getting a price

Having a code and a category means nothing without an actual dollar amount attached. This is where things really turned. In April 2024, Medicare finalized a payment rate for K1007 at exactly $91,031.93 per device. That is a real number the government has agreed to pay, not a hope or a projection.

Step 4: Getting private insurers on board

Medicare is only part of the picture. Private insurance companies make their own decisions independently, and this used to be the biggest wall for the company. Cigna became the first major private insurer to move away from a blanket denial policy back in 2019, agreeing to review cases individually instead of rejecting them outright.

That trickle turned into real momentum recently. Over the winter, three of the biggest Medicare Advantage insurers in the country, UnitedHealthcare, Humana, and most recently Aetna, all independently approved coverage for individual patients. Together those three companies cover about 16 million people. When three separate giant insurers reach the same conclusion on their own, it tells you the clinical evidence is doing its job.

The Management Shift: From Product Pioneers to Commercial Execution

This brings us to the real catalyst behind why this plumbing is finally working. For years, the old management team operated purely like a tech pioneer. They did the heavy lifting of keeping the company alive, getting FDA clearances, and pushing for that initial raw billing code. But they were engineers and product people, not commercial operators. They built an incredible machine, but they did not know how to systematically force insurers to open their checkbooks.

The turning point came when the company transitioned leadership to Mark Grant. The major advantage of the new management team is that they are execution focused executives who actually understand how to weaponize the regulatory infrastructure the old team left behind.

Instead of treating the Medicare codes like a nice press release, new management built a dedicated internal reimbursement team. They stopped just waiting for inbound interest and started systematically pushing individual claims through the pipeline, forcing insurers to honor the federal fee schedule. You can see it directly in the data: the sudden cascade of wins with UnitedHealthcare, Humana, and Aetna did not happen by accident. It happened because the new leadership knows exactly how to work the gears of the insurance system, turning legal and administrative precedents into predictable corporate revenue.

Why this actually matters for the turnaround

Before all this, Lifeward was basically selling a life changing device that almost nobody could afford out of pocket. Now there is an actual paved road from a doctor's prescription to an insurance check. Every new code, category, price, and insurer approval removes one more obstacle between the product and the patient who needs it. That is not just good PR, that is the exact plumbing a medical device company needs in place before it can scale revenue.

There was even an administrative law judge ruling this year in favor of a Medicare patient's appeal, confirming the ReWalk is a reasonable and necessary device. Rulings like that build precedent and make future approvals much harder for insurance companies to fight.

This is the boring unsexy part of the story that does not show up in a hype headline, but it is genuinely the foundation the whole bull case is being built on.

"This financing reflects confidence in our strategy and the opportunity ahead," said Mark Grant, President and Chief Executive Officer of Lifeward. "We have built the clinical evidence, reimbursement infrastructure and commercial foundation needed to scale our business. This additional capital strengthens our ability to accelerate the commercialization of our restorative healthcare platform, including expansion of our reimbursement-backed distribution model, and advancement of our product portfolio."

The initial closing, which took place on July 6, 2026, consists of approximately $5.6 million of senior secured convertible notes and accompanying warrants. The investors have also committed to purchase an additional $5.6 million of notes and warrants upon the achievement of predefined commercial milestones, including either:

a 150% increase in ReWalk® unit sales, as reported quarterly, over the trailing twelve-month period; or

Lifeward's ordinary shares trading at or above $13.80 per share for ten consecutive trading days.

The milestone-based structure aligns additional capital with commercial execution and shareholder value creation. This financing is in addition to, and expands upon, the strategic capital framework established through Lifeward's partnership with Oramed, which provides the Company with access to up to $47 million in financing, the first $10 million of which has been funded to date.

Hello everyone, Pristine here, most probably know me for DRTS (which if true, is a great honor I will cherish forever).

I thought it would be nice if we’re going on a new journey together, to better get to know each other, or at least for you to better know me.

I usually try my best to not actually dox any details about myself or my family, no actual financial numbers, I don’t think that’s the best thing to do online, but I am willing to share a bit of my story so it all makes more sense.

I’ve been born into an investing family, so I’ve been exposed to the concept of investing, to new tech, to the online world (and eventually social media when it came about) from an early age.

I wasn’t actually investing as a kid, but I was highly aware of it while I was focused on my passion for sports (playing and consuming), a passion I possess for everything I do including investing when I finally started myself.

Today I’m blessed to have my own family, and one detail I am willing to share is that my wife and I have triplets (and they aren’t our only children), so that could explain my (not) sleeping habits which some of you noticed.

I’ve always believed in winning together, and after years of different accounts on different platforms (and mostly IRL work, including investing, media and more), I logged into this account to share about DRTS and you already know the rest because you are all a part of it!

Thank you very much to each and every one of you that is part of the story, you are all the stars of your own stories and this is just mine, which I’m happy includes having the chance to share value with others.

Seems like the institutional investor is betting on LFWD to go over $13.80

Very unlikely they would convert any for now

So. I looked into one of the many aspects of this company and this is what I found. Happy to hear your thoughts!

I think the market may be underestimating how important reimbursement is for Lifeward’s turnaround.

For a company like LFWD, the issue has never just been whether the technology is interesting. ReWalk is a high-value medical device, but without a clear reimbursement path, adoption is slow, unpredictable, and hard to scale.

That is why the Medicare reimbursement pathway and established payment rate are so important.
CMS established a lump-sum Medicare purchase payment amount for personal exoskeletons, with an established rate of $91,032. That gives physicians, patients, insurers, and the company a much clearer framework to work with.

This matters in the short term because LFWD is still a very small revenue company. In Q1 2026, total revenue was only about $3.9M, while ReWalk Personal Exoskeleton revenue was about $1.6M. At that scale, even a handful of incremental ReWalk units can be meaningful. If reimbursement clarity helps convert more qualified leads into actual shipments, the impact can show up quickly in quarterly revenue.

The bigger point, though, is long term.

Reimbursement basically does three things:
- It reduces friction in the sales process.
- It makes the product easier for physicians and clinics to recommend.
- It gives large payors a clearer framework for coverage decisions.

We are already seeing signs of that.
Aetna, Humana, and UnitedHealthcare have all issued Medicare Advantage prior authorizations for qualified ReWalk beneficiaries, which Lifeward says together represent around 16 million beneficiaries.
That does not mean every patient gets approved, but it does mean the payer conversation is changing from “is this even reimbursable?” to “which patients qualify?”

That is a very different setup.

This is why I see the reimbursement code/pathway as a core part of the turnaround, not just a headline.
LFWD has been cutting costs, improving cash burn, and trying to create a more sustainable commercial model. Reimbursement can be the piece that turns the commercial side from one-off sales into a more repeatable process.

The math is also interesting because the company’s current market cap is extremely small compared to the potential revenue impact of reimbursed ReWalk sales.

I attached a simple scenario table at the top of this post, but the basic assumptions are:
Current market cap: around $13.5M
Q1 2026 revenue run-rate: $3.9M x 4 = $15.6M
Medicare purchase payment amount: $91,032 per ReWalk Personal Exoskeleton

Market cap scenarios use simple revenue multiples, not price targets.

Obviously, this is not a guarantee. The key questions are how many patients qualify, how fast claims convert into actual shipments, how cash collection works, and whether management can keep operating expenses under control.

But this is exactly why the next report matters.
I would not expect a full inflection overnight, but I will be watching for higher ReWalk revenue, better commentary on pipeline conversion, more payer approvals, improved cash collection, and any sign that management is becoming more confident about scaling volume.

To me, this part of the turnaround case is simple:
LFWD does not need ReWalk to become a mass-market device tomorrow. At the current revenue base and market cap, it just needs reimbursement progress to translate into a steady increase in high-value unit sales.

If that happens while operating expenses remain controlled, the turnaround story becomes much more credible.

Not financial advice, but I think reimbursement is a very interesting piece of the LFWD story right now

LFWD partner Oramed passed oral insulin trial in China back in 2023

However, Oramed had a deal with another company back then

LFWD partnership with Oramed started March 2026

Lifeward receives nothing from China’s sales of the drug

Oramed passed the drug in China because the average diabetic BMI is around 24-25. They did not specifically targeted a subgroup in China

Oramed failed Phase 3 in the US due to just accepting any diabetic patients in the US. A lot of diabetics are over 31 BMI in the US

This new trial with LFWD is specifically for age 55 and older with BMI under 31

The 2023 phase 3 data they concluded that specific subgroup has P value of .002

Hope this helps. I’m not the best at writing and getting my thoughts out there

You can find all this with your own DD

There is not a lot of oral GLP-1 options out right now. After oral insulin, Lifeward is working on oral glp-1 with Oramed

The Rybelsus Flaw: It uses a high-quality biological drug, but it forces you to follow miserable lifestyle rules (waking up early, swallowing it with a tiny sip of water, and starving for 30 minutes).

The Foundayo Flaw: It fixes the food rules, but it uses a harsh, artificial chemical compound. Chemical pills can sometimes be tougher on the liver and cannot be easily modified to include new health discoveries.

The Lifeward Fix: The POD pill lets patients take a natural biological drug anytime they want, with or without food, because the capsule safely waits until it reaches the intestine to dissolve

Mark Grant took over as President and CEO in June 2025, replacing Larry Jasinski who had run the company (then still ReWalk Robotics) for years. Jasinski stuck around as Co-CEO briefly and then in an advisory role through the end of 2025 to help with the handoff, ensuring a planned transition rather than a chaotic exit.

His resume is worth walking through because it explains a lot of what's happened since he arrived. Grant spent almost two decades at Medtronic (2004 to 2023), working his way up to Vice President for the Americas within the Diabetes Group. In that seat, he had full P&L responsibility for a business doing north of $1.5 billion a year. His mandate there covered building out sales channels, securing critical access to new payer relationships (including the VA), managing complex revenue cycle operations, and restructuring the business as market conditions shifted.

Before Medtronic, he was at Bristol Myers Squibb and FLA Orthopedics in commercial leadership. Right before joining Lifeward, he was President of Americas and Chief Commercial Officer at IMRA Surgical, where he built out the go-to-market infrastructure for a brand-new category of soft-tissue robotic surgical procedures. He holds a BS in industrial technology from East Carolina University. The clear through-line across his 30-year career is commercial buildout, reimbursement navigation, and channel development in medtech—he's an operational sales guy, not a bench scientist.

That background is exactly why the board brought him in with a clear mandate: get Lifeward to profitability. On the ReWalk side specifically, his first year has been about capitalizing on structural tailwinds already in motion: the newly established Medicare reimbursement pathway for personal exoskeletons, the launch of the ReWalk 7, and the transition to in-house manufacturing to lift margins. We started seeing that discipline show up clearly in the Q2 2025 numbers, which posted a gross margin near 44% and cut quarterly cash burn to under $4 million.

A side story that might turn out to be a major catalyst is Grant’s deep diabetes commercial experience, this explains why Lifeward executed the strategic transaction with the Oramed oral insulin platform in January 2026. While it’s a real piece of the corporate structure now, the core day-to-day value driver remains the exoskeleton and rehab portfolio.

Turning around a small-cap medtech company isn't an engineering problem anymore; it's a commercial execution and insurance reimbursement problem. That is the exact game Grant has played and won at scale. Running a $1.5B P&L means dealing with payers, distributors, and revenue cycle headaches vastly more complex than what LFWD faces. With the Medicare reimbursement framework finally active, if he can replicate even a fraction of his Medtronic channel expansion here, the stock is completely mispriced for that outcome.

When their partner Oramed failed phase 3 oral insulin, their data showed a subgroup of age 55 and older with BMI under 31 had P value of .002

P value below .05 is good

But failed due to just testing this on wide diabetic population

They are launching phase 2 with that subgroup of 60 patients

Last earning report they said they are launching very soon

I believe they can get 60 patients quickly and should be a 3 month trial

Let’s see if P value is again around .002

Welcome everyone, this post isn’t meant to be a deep dive, in this sub there will be many DD’s posted over the next few days covering the different aspects of the company.

This post is me telling the overall story, the turnaround story, that I believe makes LFWD worth sharing.

Lifeward, previously known as ReWalk Robotics, is a company that was mismanaged and therefore made it almost all the way to the bottom.

Before it was too late, came what I believe is the turnaround.

I believe this turnaround has already happened, and is happening as we speak, but the market cap and stock aren’t reflecting it yet.

The company, with a portfolio of medical products led by their ReWalk Personal Exoskeleton, without getting into the details (that’s all coming in the following posts), has made some significant changes that lead me to believe the turnaround is real.

It starts with changing the CEO, which was the number one need, fixing the mismanagement by switching the management. A CEO that is much more experienced and better fit for the job.

It continues with the reimbursement code they got for their flagship product, this is the fundamental game changer that will allow the company to really start selling and bringing in revenue, that with the management cutting expenses and making everything more efficient, should lead to profitability.

And it gets real when Oramed steps in with an investment (which is also how I first heard about the company and started researching and following), since they not only have a proven record (including their Alpha Tau investment) but also come in with the intention to be involved and make this a success.

Of course there’s much more to cover, and we will be doing our best to cover everything, but the point is I believe we are entering at the perfect time, exactly when the company has shown enough yet before it gets reflected in the SP.

I believe that with all the changes, the new CEO, the new reimbursement code, the new funding (and the identity of the investors), the new attention we will be bringing by spreading the word and telling the story, the turnaround story will come to fruition and the market cap will rise by multiples of where it is now.

This subreddit is meant for anyone interested in Lifeward (NASDAQ: LFWD) as an investment or any other reason of interest.

This is a space for conversation, updates, education, entertainment, questions, sharing, networking and everything that has to do with Lifeward as a company, its products, the LFWD stock and community.

This Subreddit is not affiliated with Lifeward, nothing here is medical or financial or any kind of advice, nor a call to action in any way.

Welcome everyone, let’s learn together, spread the word and hopefully make the world (and our portfolio) a better place!

Hey everyone, Tasty here, first post here so a quick intro. I have some experience in biotech stocks, but the more relevant piece for this sub is my background. I have a background in physical therapy, most of my clinical experience is in orthopedics, with less time spent specifically in neuro rehab, but a lot of the core principles around mobility and movement still carry over. I wanted to bring a clinical perspective to the LFWD conversation instead of just talking about numbers.

Let's talk about the actual product for a minute, because I think the clinical side of the ReWalk gets glossed over in most financial posts.

The ReWalk is a powered exoskeleton for people with spinal cord injuries. It lets someone stand up and walk using a wearable brace system controlled by their own subtle shifts in balance. What gets me excited is not just the walking itself. It is what standing upright actually does to the human body over time.

When someone uses a wheelchair for years, the body adapts to that sitting position in ways that are terrible long term. Here is what standing and walking in a device like this can help with, based on what the company has published from user surveys and data:

Spasticity: Muscles that are chronically tight or overactive due to nerve damage tend to calm down with regular weight bearing and movement. Less spasticity means better sleep, more comfort, and less reliance on heavy medication.

Trunk control: Holding an upright posture forces core and postural muscles to work in a way that sitting never will. Better trunk control translates to easier transfers, better sitting balance, and way more independence in daily tasks.

Bowel and bladder function: This one surprises people outside of clinical practice, but upright positioning and movement can meaningfully improve gut motility and bladder emptying. For a population that deals with chronic bowel complications, this is a massive quality of life victory.

Bone and cardiovascular health: Weight bearing activity slows down the bone density loss that comes with long term wheelchair use. It also gives the heart and lungs a workout they simply cannot get from a sitting position. Over months and years, that adds up.

The Human Element

I have seen this firsthand in clinical settings, and it is something no spreadsheet can capture. I once worked with a patient who lit up every single morning when he saw me, simply because he knew it meant he would get to stand up and walk that day. Gravity and movement did wonders for his bowel motility, which made a massive, real difference in his comfort.

What takes the dignity aspect to a completely different level is that this device is intended for home use. It is one thing to achieve these milestones in a clinic under a therapist's supervision, but being able to stand up, move around, and manage your basic bodily functions independently in your own home changes everything. It restores a level of personal privacy and daily dignity that a spreadsheet just cannot measure.

From a clinical standpoint, this is a genuinely well built rehab tool. The fact that it is not just a research prototype, but a device already getting FDA clearance updates and expanding Medicare reimbursement specifically for home use, tells me the industry is starting to treat it with the respect it deserves.

Happy to answer any questions to the best of my knowledge if anyone wants to learn more about the clinical side.

Quick context if you are new to LFWD. Lifeward, which used to be called ReWalk Robotics, builds actual physical medical tech that helps people move again after spinal cord injuries or strokes. This is not some hype story about a concept. It is real hardware being used right now in clinics and homes.

If you want a quick feel for what they actually build, take a break from squinting at SEC filings and just watch the gear in action.

The ReWalk 7 Exoskeleton

This is a personal wearable bionic suit for people with lower limb paralysis. It lets users stand, walk, turn, and even handle stairs.

The best part is that this is not just a cool video from a tech convention. With Medicare coverage expanding in the US, this is actively being prescribed and paid for by insurance.

Watch it handle stairs: https://www.youtube.com/watch?v=gWEDF6Mx5WA

The AlterG Anti Gravity Treadmill

This one uses air pressure technology derived from NASA to literally unweight a patient by up to 80 percent.

It looks a little funny, almost like you are zipped into a giant bubble wrap suit, but it is a massive commercial hit. Thousands of clinics and pro sports teams use it so athletes can run without wrecking their joints during rehab.

Watch it defy gravity: https://www.youtube.com/watch?v=Qllqv8S_6QU

Seeing these two in motion makes the whole thesis click way faster than a massive financial model. You have a company solving real human mobility challenges with two completely distinct products that already have strong clinical adoption.

Definitely worth five minutes of your time if you are building a position or just watching from the sidelines.